Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Find generic entry opportunities
Anticipate generic drug launch
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient|
|Abstract:||(R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or its salt shows a potent bladder relaxation effect in "isolated rat bladder smooth muscle relaxation test", dose-dependently lowers the contraction frequency of rhythmic bladder contractions in "rat rhythmic bladder contraction measurement test" and, moreover, prolongs the urination intervals in "urination functions measurement test on cyclophosphamide-induced overactive bladder model rat". Owing to these effects, the above compound is useful as a remedy for ovaractive bladder.|
|Inventor(s):||Takasu; Toshiyuki (Tsukuba, JP), Sato; Shuichi (Tsukuba, JP), Ukai; Masashi (Tsukuba, JP), Maruyama; Tatsuya (Tsukuba, JP)|
|Assignee:||Astellas Pharma Inc. (Tokyo, JP)|
Patent Claim Types:|
see list of patent claims
Back Citations: 22nd percentile
Forward Citations: 0th percentile
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Slovenia||1559427||<disabled in preview>|
|Russian Federation||2321401||<disabled in preview>|
|Russian Federation||2005117367||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.